← All trials
NCT01489566
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2011
- Primary completion
- Mar 1, 2013
- Completion date
- Aug 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.Lead sponsor
- Shandong Provincial HospitalOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Wuhan UniversityOverall official - principal investigator
- Shandong Provincial Cancer HospitalOverall official - principal investigator
- Tsinghua UniversityOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Fujian Medical UniversityOverall official - principal investigator
- Harbin Medical UniversityOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Nanjing Medical UniversityOverall official - principal investigator
- Fudan UniversityStudy director
- Fudan UniversityStudy chair
- Fudan UniversityCollaborator
- Medpace, Inc.Collaborator
- Second Military Medical UniversityOverall official - principal investigator
- Second Military Medical UniversityStudy director
- Second Military Medical UniversityStudy chair
- People's Liberation Army of ChinaOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.